Pain

[vc_row fullwidth=”true”][vc_column][vc_row_inner is_fullwidth_content=”false”][vc_column_inner][mk_fancy_title tag_name=”h1″ color=”#131415″ size=”20″ font_weight=”bolder” txt_transform=”uppercase” letter_spacing=”8″ margin_bottom=”0″ font_family=”Montserrat” font_type=”google” align=”center”]

PAIN

[/mk_fancy_title][vc_separator color=”custom” style=”double” el_width=”30″ accent_color=”rgba(84,84,84,0.5)”][mk_padding_divider size=”60″][mk_fancy_title color=”#131415″ size=”18″ font_weight=”600″ txt_transform=”uppercase” letter_spacing=”7″ margin_bottom=”25″ font_family=”Montserrat” font_type=”google”]

ABSTRACT

[/mk_fancy_title][mk_fancy_title color=”#e6936d” size=”16″ font_weight=”400″ txt_transform=”uppercase” letter_spacing=”2″ margin_bottom=”25″ font_family=”Montserrat” font_type=”google” align=”center”]

Role of the Cannabinoid System in Pain Control and Therapeutic
Implications for the Management of Acute and Chronic Pain Episodes (2006)

[/mk_fancy_title][mk_fancy_title color=”#131415″ size=”16″ line_height=”150″ margin_bottom=”25″ font_family=”Montserrat” font_type=”google”]Cannabis extracts and synthetic cannabinoids are still widely considered illegal substances. Preclinical and clinical studies have suggested that they may result useful to treat diverse diseases, including those related with acute or chronic pain. The discovery of cannabinoid receptors, their endogenous ligands, and the machinery for the synthesis, transport, and degradation of these retrograde messengers, has equipped us with neurochemical tools for novel drug design. Agonist-activated cannabinoid receptors, modulate nociceptive thresholds, inhibit release of pro-inflammatory molecules, and display synergistic effects with other systems that influence analgesia, especially the endogenous opioid system. Cannabinoid receptor agonists have shown therapeutic value against inflammatory and neuropathic pains, conditions that are often refractory to therapy. Although the psychoactive effects of these substances have limited clinical progress to study cannabinoid actions in pain mechanisms, preclinical research is progressing rapidly. For example, CB1-mediated suppression of mast cell activation responses, CB2-mediated indirect stimulation of opioid receptors located in primary afferent pathways, and the discovery of inhibitors for either the transporters or the enzymes degrading endocannabinoids, are recent findings that suggest new therapeutic approaches to avoid central nervous system side effects. In this review, we will examine promising indications of cannabinoid receptor agonists to alleviate acute and chronic pain episodes. Recently, Cannabis sativa extracts, containing known doses of tetrahydrocannabinol and cannabidiol, have granted approval in Canada for the relief of neuropathic pain in multiple sclerosis. Further double-blind placebo-controlled clinical trials are needed to evaluate the potential therapeutic effectiveness of various cannabinoid agonists-based medications for controlling different types of pain.[/mk_fancy_title][mk_button dimension=”flat” size=”medium” letter_spacing=”7″ icon=”mk-moon-book” icon_anim=”side” url=”https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2430692/?report=reader” target=”_blank” nofollow=”true” align=”right” button_custom_width=”400″ bg_color=”#000000″ btn_hover_bg=”#e6936d” btn_hover_txt_color=”#ffffff”]READ THE STUDY[/mk_button][/vc_column_inner][/vc_row_inner][vc_row_inner is_fullwidth_content=”false”][vc_column_inner][mk_padding_divider size=”60″][mk_fancy_title color=”#131415″ size=”18″ font_weight=”600″ txt_transform=”uppercase” letter_spacing=”7″ margin_bottom=”25″ font_family=”Montserrat” font_type=”google”]

ABSTRACT

[/mk_fancy_title][mk_fancy_title color=”#e6936d” size=”16″ font_weight=”400″ txt_transform=”uppercase” letter_spacing=”2″ margin_bottom=”25″ font_family=”Montserrat” font_type=”google” align=”center”]

Cannabis-based medicines for chronic neuropathic pain in adults.
(2018)

[/mk_fancy_title][mk_fancy_title color=”#131415″ size=”16″ line_height=”150″ margin_bottom=”25″ font_family=”Montserrat” font_type=”google”]This review is one of a series on drugs used to treat chronic neuropathic pain. Estimates of the population prevalence of chronic pain with neuropathic components range between 6% and 10%. Current pharmacological treatment options for neuropathic pain afford substantial benefit for only a few people, often with adverse effects that outweigh the benefits. There is a need to explore other treatment options, with different mechanisms of action for treatment of conditions with chronic neuropathic pain. Cannabis has been used for millennia to reduce pain. Herbal cannabis is currently strongly promoted by some patients and their advocates to treat any type of chronic pain.[/mk_fancy_title][mk_button dimension=”flat” size=”medium” letter_spacing=”7″ icon=”mk-moon-book” icon_anim=”side” url=”https://www.ncbi.nlm.nih.gov/pubmed/29513392″ target=”_blank” nofollow=”true” align=”right” button_custom_width=”400″ bg_color=”#000000″ btn_hover_bg=”#e6936d” btn_hover_txt_color=”#ffffff”]READ THE STUDY[/mk_button][/vc_column_inner][/vc_row_inner][/vc_column][/vc_row][vc_row fullwidth=”true”][vc_column][vc_row_inner is_fullwidth_content=”false”][vc_column_inner][mk_padding_divider size=”100″][mk_fancy_title color=”#131415″ size=”18″ font_weight=”600″ txt_transform=”uppercase” letter_spacing=”7″ margin_bottom=”25″ font_family=”Montserrat” font_type=”google”]

RECOMMENDED PRODUCTS

[/mk_fancy_title][mk_products columns=”4″ image_size=”Condition Thumbnail” display=”top_rated” count=”4″ orderby=”rand” posts=”2986, 1400, 1471, 2650, 2653″][mk_padding_divider size=”25″][/vc_column_inner][/vc_row_inner][/vc_column][/vc_row][vc_row fullwidth=”true”][vc_column][mk_padding_divider size=”100″][mk_divider style=”thin_solid” thin_single_color=”#959595″ margin_top=”40″ margin_bottom=”0″][/vc_column][/vc_row]

Share on Google+

Leave a Reply